Search research articles
Contact Us
Filters
Showing results (131-140 of 401) with videos related to
Page
of 41
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2013
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial
Brian I Rini, Joaquim Bellmunt, Jill Clancy, et al.
Cancer
|
October 5, 2002
A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma
Apurva A Desai, Nicholas J Vogelzang, Brian I Rini, et al.
Cancer
|
June 29, 2004
Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma
Brian I Rini, Vivian Weinberg, Vanessa Shaw, et al.
BJU International
|
January 20, 2011
Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma
Jorge A Garcia, Tarek Mekhail, Paul Elson, et al.
British Journal of Cancer
|
June 27, 2020
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events
Viktor Grünwald, Martin H Voss, Brian I Rini, et al.
Therapeutic Advances in Urology
|
February 17, 2017
Specific immunotherapy in renal cancer: a systematic review
Armin Hirbod-Mobarakeh, Hesam Addin Gordan, Zahra Zahiri, et al.
Cancer
|
December 22, 2005
Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma
Brian I Rini, Vivian Weinberg, Sarah Dunlap, et al.
Cancer
|
October 21, 2010
The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib
Naveen S Basappa, Paul Elson, Ali-Reza Golshayan, et al.
Frontiers in Oncology
|
January 8, 2021
Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports
Matthew D Tucker, Kathryn E Beckermann, Jennifer B Gordetsky, et al.
Cancer Biology & Therapy
|
May 21, 2014
Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers
Kriti Mittal, Henry Koon, Paul Elson, et al.
Page
of 41
Search research articles
Search
Showing results (131-140 of 401) with videos related to
Sort By:
Page
of 41
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 4, 2013
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial
Brian I Rini, Joaquim Bellmunt, Jill Clancy, et al.
Cancer
|
October 5, 2002
A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma
Apurva A Desai, Nicholas J Vogelzang, Brian I Rini, et al.
Cancer
|
June 29, 2004
Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma
Brian I Rini, Vivian Weinberg, Vanessa Shaw, et al.
BJU International
|
January 20, 2011
Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma
Jorge A Garcia, Tarek Mekhail, Paul Elson, et al.
British Journal of Cancer
|
June 27, 2020
Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events
Viktor Grünwald, Martin H Voss, Brian I Rini, et al.
Therapeutic Advances in Urology
|
February 17, 2017
Specific immunotherapy in renal cancer: a systematic review
Armin Hirbod-Mobarakeh, Hesam Addin Gordan, Zahra Zahiri, et al.
Cancer
|
December 22, 2005
Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma
Brian I Rini, Vivian Weinberg, Sarah Dunlap, et al.
Cancer
|
October 21, 2010
The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib
Naveen S Basappa, Paul Elson, Ali-Reza Golshayan, et al.
Frontiers in Oncology
|
January 8, 2021
Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports
Matthew D Tucker, Kathryn E Beckermann, Jennifer B Gordetsky, et al.
Cancer Biology & Therapy
|
May 21, 2014
Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers
Kriti Mittal, Henry Koon, Paul Elson, et al.
Page
of 41